- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in TCAR procedures - - FDA approval of the original CGuard delivery system anticipated in Q3 2026 - - On track for expected FDA approval of the CGuard Prime 80 cm for TCAR procedures in H2 2026, potentially doubling the Company’s addressable market - MIAMI, May 04, 2026 (GLOBE NEWSWIR ...

InspireMD is set to release its Q1 2026 financial results on May 4, 2026, with analysts projecting $2.70 million in revenue and an estimated -$0.19 EPS. The medical device company recently initiated a voluntary U.S. recall for its CGuard Prime 135 cm system due to performance issues, which may impact the upcoming financial report. Despite the recall, InspireMD reported a 53% increase in global unit sales and received FDA approval for its CGUARDIANS III study, while current financials show a strong current ...